• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间歇性跛行研究中的报告结局——迈向核心结局集的第一步:系统评价。

Reported outcomes in studies of intermittent claudication - first step toward a core outcome set: systematic review.

机构信息

Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.

Leicester Vascular Institute, University Hospitals of Leicester NHS Trust, Leicester, UK.

出版信息

BJS Open. 2024 Oct 29;8(6). doi: 10.1093/bjsopen/zrae126.

DOI:10.1093/bjsopen/zrae126
PMID:39485886
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11529788/
Abstract

INTRODUCTION

This review aimed to compile an exhaustive list of all outcome measures and identify different characteristics of the outcomes reported in studies of intermittent claudication as the first step in developing a core outcome set for intermittent claudication.

METHOD

Medline and Embase were searched for all studies including individuals with intermittent claudication and reporting ≥1 outcome from January 2015 to August 2024. Abstract, full text screening and data extraction were performed by two investigators independently. All reported outcome measures were extracted verbatim and categorized by Dodd's domains (Core Outcome Measures in Effectiveness Trials registration: COMIC Study, 1590; https://www.comet-initiative.org/Studies/Details/1590).

RESULTS

4985 studies were screened and 408 were included. A total of 541 unique outcomes across 25 Dodd's domains were identified. Ankle-brachial pressure index was the most frequently reported outcome. Among the 541 unique outcomes, 386 outcomes were only reported once. Only 38.9% of the studies exclusively included patients with intermittent claudication. Patient-reported outcomes were reported in 36.2% of studies. There were wide variations in the definition of commonly used outcome measures (for example, major adverse limb event and primary patency) across different studies.

CONCLUSION

There is substantial heterogeneity in reported outcomes in studies of intermittent claudication. Most reported outcomes are clinical/physiology oriented rather than patient centred. Development of a core outcome set for intermittent claudication is vital to improve and standardize reporting in future research.

摘要

简介

本综述旨在编制一份详尽的所有结局指标清单,并确定间歇性跛行研究报告的结局的不同特征,这是为间歇性跛行制定核心结局集的第一步。

方法

检索了 Medline 和 Embase 中所有纳入间歇性跛行患者且报告至少 1 项结局的研究,检索时间范围为 2015 年 1 月至 2024 年 8 月。两名研究者独立进行摘要、全文筛选和数据提取。逐字提取所有报告的结局指标,并按 Dodd 领域进行分类(有效性试验注册的核心结局测量:COMIC 研究,1590;https://www.comet-initiative.org/Studies/Details/1590)。

结果

筛选出 4985 篇研究,纳入 408 篇。共确定了 25 个 Dodd 领域的 541 个独特结局指标。踝肱血压指数是最常报告的结局。在 541 个独特的结局指标中,386 个结局仅报告了一次。只有 38.9%的研究仅纳入间歇性跛行患者。36.2%的研究报告了患者报告的结局。在不同研究中,常用结局指标的定义存在很大差异(例如,主要肢体不良事件和原发性通畅率)。

结论

在间歇性跛行的研究中,报告的结局存在很大的异质性。大多数报告的结局都是以临床/生理学为导向,而不是以患者为中心。制定间歇性跛行的核心结局集对于提高和规范未来研究的报告至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/027c/11529788/19466e509fe8/zrae126f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/027c/11529788/a20bf10ce1c5/zrae126f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/027c/11529788/19466e509fe8/zrae126f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/027c/11529788/a20bf10ce1c5/zrae126f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/027c/11529788/19466e509fe8/zrae126f2.jpg

相似文献

1
Reported outcomes in studies of intermittent claudication - first step toward a core outcome set: systematic review.间歇性跛行研究中的报告结局——迈向核心结局集的第一步:系统评价。
BJS Open. 2024 Oct 29;8(6). doi: 10.1093/bjsopen/zrae126.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Omega-3 fatty acids for intermittent claudication.ω-3 脂肪酸治疗间歇性跛行。
Cochrane Database Syst Rev. 2024 Oct 29;10(10):CD003833. doi: 10.1002/14651858.CD003833.pub5.
4
Propionyl-L-carnitine for intermittent claudication.丙酰肉碱治疗间歇性跛行。
Cochrane Database Syst Rev. 2021 Dec 26;12(12):CD010117. doi: 10.1002/14651858.CD010117.pub2.
5
Cilostazol for intermittent claudication.西洛他唑治疗间歇性跛行。
Cochrane Database Syst Rev. 2021 Jun 30;6(6):CD003748. doi: 10.1002/14651858.CD003748.pub5.
6
Gene therapy for peripheral arterial disease.外周动脉疾病的基因治疗
Cochrane Database Syst Rev. 2018 Oct 31;10(10):CD012058. doi: 10.1002/14651858.CD012058.pub2.
7
Exercise for intermittent claudication.间歇性跛行的运动疗法
Cochrane Database Syst Rev. 2017 Dec 26;12(12):CD000990. doi: 10.1002/14651858.CD000990.pub4.
8
Ankle-brachial index in patients with intermittent claudication is a poor indicator of patient-centered and clinician-based evaluations of functional status.间歇性跛行患者的踝臂指数是患者为中心和基于临床医生的功能状态评估的不良指标。
J Vasc Surg. 2019 Mar;69(3):906-912. doi: 10.1016/j.jvs.2018.07.039. Epub 2019 Jan 6.
9
Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.下肢外周动脉疾病的支架置入术:一项基于证据的分析。
Ont Health Technol Assess Ser. 2010;10(18):1-88. Epub 2010 Sep 1.
10
Pentoxifylline for intermittent claudication.己酮可可碱用于间歇性跛行
Cochrane Database Syst Rev. 2020 Oct 16;10(10):CD005262. doi: 10.1002/14651858.CD005262.pub4.

引用本文的文献

1
Core outcome sets in symptomatic peripheral artery disease, COS-PAD: Study protocol for developing core outcome sets in symptomatic PAD utilising systematic reviews, interviews, and delphi consensus.症状性外周动脉疾病核心结局集(COS-PAD):利用系统评价、访谈和德尔菲共识法制定症状性外周动脉疾病核心结局集的研究方案
PLoS One. 2025 Jul 17;20(7):e0328453. doi: 10.1371/journal.pone.0328453. eCollection 2025.

本文引用的文献

1
Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication.编辑推荐——欧洲血管外科学会(ESVS)2024年无症状下肢外周动脉疾病和间歇性跛行管理临床实践指南
Eur J Vasc Endovasc Surg. 2024 Jan;67(1):9-96. doi: 10.1016/j.ejvs.2023.08.067. Epub 2023 Nov 10.
2
Exploring the Reporting Standards of Randomised Controlled Trials Involving Endovascular Interventions for Peripheral Arterial Disease: A Systematic Review.探索外周动脉疾病血管内介入随机对照试验的报告标准:一项系统评价。
Eur J Vasc Endovasc Surg. 2024 Jan;67(1):155-164. doi: 10.1016/j.ejvs.2023.08.066. Epub 2023 Sep 9.
3
Introduction to the special section "Reducing research waste in (health-related) quality of life research".
“减少(与健康相关的)生活质量研究中的研究浪费”专题介绍
Qual Life Res. 2022 Oct;31(10):2881-2887. doi: 10.1007/s11136-022-03194-z.
4
Patient-Reported Outcome Measures in Symptomatic, Non-Limb-Threatening Peripheral Artery Disease: A State-of-the-Art Review.有症状的非肢体威胁性外周动脉疾病患者报告结局测量:最新综述
Circ Cardiovasc Interv. 2022 Jan;15(1):e011320. doi: 10.1161/CIRCINTERVENTIONS.121.011320. Epub 2021 Dec 23.
5
Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association.下肢外周动脉疾病:当代流行病学、管理差距与未来方向:美国心脏协会科学声明。
Circulation. 2021 Aug 31;144(9):e171-e191. doi: 10.1161/CIR.0000000000001005. Epub 2021 Jul 28.
6
Epidemiology of Peripheral Artery Disease and Polyvascular Disease.外周动脉疾病和多血管疾病的流行病学。
Circ Res. 2021 Jun 11;128(12):1818-1832. doi: 10.1161/CIRCRESAHA.121.318535. Epub 2021 Jun 10.
7
Development of Core Outcome Sets for People Undergoing Major Lower Limb Amputation for Complications of Peripheral Vascular Disease.为外周血管疾病并发症行大截肢术的人群制定核心结局集。
Eur J Vasc Endovasc Surg. 2020 Nov;60(5):730-738. doi: 10.1016/j.ejvs.2020.06.021. Epub 2020 Aug 11.
8
A Comparison of Quality of Life in Elderly Patients with Intermittent Claudication and Chronic Limb-Threatening Ischemia.间歇性跛行老年患者与慢性肢体威胁性缺血患者生活质量的比较
Ann Vasc Surg. 2020 Nov;69:285-291. doi: 10.1016/j.avsg.2020.05.048. Epub 2020 Jun 3.
9
Evidence synthesis for tackling research waste.应对研究浪费的证据综合分析
Nat Ecol Evol. 2020 Apr;4(4):495-497. doi: 10.1038/s41559-020-1141-6.
10
Differential burden of peripheral artery disease.外周动脉疾病的差异负担。
Lancet Glob Health. 2019 Aug;7(8):e980-e981. doi: 10.1016/S2214-109X(19)30293-1.